Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.59 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.55 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13914028 | 0.89 | CTSK (0.63) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL21485271 | 0.89 | CTSK (0.70) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL4466886 | 0.87 | CTSK (0.58) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL4480571 | 0.87 | CASP3 (0.55) | CTSKCTSLCTSSCTSB | |
| SCHEMBL9600765 | 0.86 | CTSK (0.63) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL13925094 | 0.85 | CTSK (0.60) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL4457522 | 0.85 | CTSK (0.57) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL4470141 | 0.85 | CTSB (0.56) | CTSKCTSLCTSSCTSB | |
| SCHEMBL23133192 | 0.84 | CTSK (0.56) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL20257141 | 0.84 | CTSK (0.56) | CTSKCTSLCTSSCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | claimed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | claimed |
| EP-1628674-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | Cytovia, Inc. (US) | 2006-03-01 | — | — | EP | claimed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | claimed |
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | disclosed |
| EP-1628674-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | Cytovia, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | ACE, ACE2, TMPRSS2 | CTSK 72/4885CTSL 27/4885CTSS 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.